GO:0031593 polyubiquitin modification-dependent protein binding

Polyubiquitin modification-dependent protein binding (GO:0031593) is a molecular function defined as binding to a protein upon poly-ubiquitination of the target protein. This activity is fundamental to the ubiquitin code, where distinct polyubiquitin chain linkages serve as signals for diverse cellular outcomes, including proteasomal degradation, DNA damage repair, and inflammatory signaling. Proteins that execute this function typically contain ubiquitin-binding domains (UBDs) that selectively recognize polyubiquitinated substrates, ensuring spatiotemporal specificity in cellular responses. The importance of GO:0031593 extends to human disease. For example, integrated network analyses of hypertrophic cardiomyopathy have identified key genes involved in ubiquitin-mediated processes, highlighting the role of polyubiquitin-dependent binding in cardiac pathology. Similarly, circular RNA expression profiles in pre-eclampsia suggest that ubiquitin-related pathways may contribute to pregnancy complications. Understanding this molecular function is therefore critical for uncovering disease mechanisms and identifying therapeutic targets. Researchers studying GO:0031593 require robust experimental models to interrogate the function of polyubiquitin-binding proteins. CRISPR-based gene editing enables precise knockout, point mutation, and knock-in of genes encoding UBD-containing proteins, facilitating causal inference in disease models [1,2]. This article provides a comprehensive overview of the mechanism, key genes, and research methods for studying polyubiquitin modification-dependent protein binding.

GO:0031593, polyubiquitin modification-dependent protein binding, is defined by QuickGO as the binding to a protein upon poly-ubiquitination of the target protein. In other words, it is a molecular function where a protein selectively recognizes and binds to another protein only when the latter has been modified by a polyubiquitin chain. This binding is modification-dependent, meaning it requires the covalent attachment of multiple ubiquitin molecules to the target protein. The function is executed by proteins containing ubiquitin-binding domains that interact with polyubiquitin chains, thereby translating the ubiquitin signal into downstream cellular events.

Polyubiquitin modification-dependent protein binding is a cornerstone of cellular proteostasis and signaling. By selectively recognizing polyubiquitinated substrates, proteins with this function ensure that ubiquitin signals are faithfully translated into appropriate cellular responses, such as proteasomal degradation or DNA repair. Disruption of this activity can lead to accumulation of damaged proteins, impaired stress responses, and disease. For instance, in hypertrophic cardiomyopathy, altered expression of genes involved in ubiquitin-dependent processes has been observed, suggesting that dysregulated polyubiquitin binding contributes to cardiac remodeling. In pre-eclampsia, circular RNA profiles point to potential involvement of ubiquitin-related pathways in placental dysfunction. Thus, understanding GO:0031593 is essential for both basic biology and translational research.

The following genes encode proteins that either exhibit polyubiquitin modification-dependent protein binding activity or are critically involved in the ubiquitin-proteasome system related to this function.

The activity of polyubiquitin modification-dependent protein binding is regulated at multiple levels. Ubiquitin chain linkage type and length dictate which UBD-containing proteins are recruited. E3 ligases and deubiquitinases dynamically modify chains, thereby controlling binding. Post-translational modifications of the binding proteins themselves, such as phosphorylation, can modulate their affinity for polyubiquitin. In disease contexts, altered expression of regulatory circular RNAs may impact these processes, as suggested in pre-eclampsia. Additionally, stress conditions can induce the expression of shuttling proteins like RAD23 and UBQLN to enhance clearance of polyubiquitinated proteins.

Hypertrophic cardiomyopathy (HCM) is a common inherited cardiac disorder characterized by thickening of the heart muscle. Integrated network analysis of differential lncRNA and gene expression in HCM identified key genes involved in ubiquitin-mediated proteolysis, suggesting that dysregulated polyubiquitin modification-dependent protein binding contributes to disease pathogenesis. Specifically, alterations in the ubiquitin-proteasome system may lead to impaired clearance of misfolded proteins in cardiomyocytes, exacerbating cardiac hypertrophy and dysfunction.

Pre-eclampsia is a pregnancy-specific disorder characterized by hypertension and proteinuria. A nested case-control study of circular RNA expression profiles in peripheral blood of pregnant women with pre-eclampsia revealed differential expression of circRNAs, some of which may regulate genes involved in ubiquitin-dependent processes. This suggests that polyubiquitin modification-dependent protein binding could play a role in the pathophysiology of pre-eclampsia, potentially through effects on placental development and vascular function.

Many proteins with polyubiquitin modification-dependent binding activity are critical for DNA repair and cell cycle control. For example, RAP80/UIMC1 binds K63-polyubiquitin at DNA damage sites to recruit BRCA1, and loss of this function leads to genomic instability and breast cancer predisposition. Similarly, SQSTM1/p62-mediated recognition of polyubiquitinated proteins in autophagy affects cancer cell survival under stress.

Neurons are particularly vulnerable to proteotoxic stress. Mutations in UBQLN2, which encodes a protein that binds polyubiquitinated substrates, cause amyotrophic lateral sclerosis (ALS) and frontotemporal dementia. Dysfunction of polyubiquitin-dependent binding leads to accumulation of ubiquitinated protein aggregates, a hallmark of many neurodegenerative diseases.

AP-MS is used to identify proteins that bind polyubiquitinated substrates. By using tandem ubiquitin-binding entities (TUBEs) or specific UBDs as baits, researchers can capture polyubiquitinated proteins and their interacting partners. This method has been instrumental in mapping the ubiquitin interactome and identifying key players in diseases like HCM.

PLA allows in situ detection of protein-protein interactions, such as the binding between a UBD-containing protein and a polyubiquitinated target. This technique provides spatial information and can be applied to tissue sections, offering insights into disease-specific interactions.

CRISPR knockout and activation screens enable systematic interrogation of genes involved in polyubiquitin modification-dependent binding. Libraries targeting UBD-containing proteins or E3 ligases can reveal modifiers of drug response or stress survival. Such screens have been used to identify key genes in HCM and pre-eclampsia [1,2].

Integrated network analysis of transcriptomic data, including lncRNA and mRNA expression, can identify hub genes related to polyubiquitin-dependent processes. This approach was used to pinpoint key genes in hypertrophic cardiomyopathy and to analyze circRNA profiles in pre-eclampsia.

Researchers studying polyubiquitin modification-dependent protein binding-related genes often need to determine whether a candidate gene is causally involved in a specific cellular process or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to enable precise genetic manipulation, from knockout to knock-in, supported by advanced screening and bioinformatics.

Polyubiquitin modification-dependent protein binding (GO:0031593) is a fundamental molecular function that interprets the ubiquitin code to control protein fate and cellular signaling. Its dysregulation is linked to a spectrum of human diseases, including hypertrophic cardiomyopathy, pre-eclampsia, cancer, and neurodegeneration [1,2]. Advances in CRISPR-based gene editing and functional genomics now allow researchers to precisely interrogate the causal roles of UBD-containing proteins. EDITGENE's comprehensive services empower scientists to accelerate discoveries in this critical area.